Clinical Trial
TRIUMPH-1 completes enrolment ahead of primary readout window
The pivotal obesity study has closed enrolment, with the 72-week primary endpoint expected to report in the coming quarters.
1 Sept 2026
Editorial record
News
Retatrutide Developments
Concise, sourced summaries of the developments that change how retatrutide's clinical and regulatory outlook should be read.
Developments
All developments
Official FDA, EMA and Eli Lilly disclosures detected by automated source monitoring, alongside editorial records. Every entry links to its source document.
Read Analysis
Regulatory
What retatrutide's regulatory pathway could look like
An analysis of the filings, endpoints and outcome data that typically precede a submission for an obesity indication.
26 Aug 2026
Editorial record
Research
Review examines glucagon receptor contribution to weight loss
Investigators assess how the glucagon arm of triple agonism may add to energy expenditure beyond incretin effects.
22 Aug 2026
Editorial record
Safety
Gastrointestinal events remain the most frequently reported findings
Nausea, vomiting and constipation dominate reported adverse events, mostly mild to moderate and dose-escalation related.
16 Aug 2026
Editorial record
Eli Lilly and Company
criticalLilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S.
12 Aug 2026
Detected from official source — editorial confirmation pending
Efficacy
Dose-response signal persists at the highest maintenance doses
Reported weight-change curves had not clearly plateaued at the end of the treatment period in earlier-phase studies.
10 Aug 2026
Editorial record
Eli Lilly
Manufacturing capacity expansion continues across incretin portfolio
Ongoing capital investment is positioned to support supply for a broader pipeline of injectable metabolic medicines.
5 Aug 2026
Editorial record
Eli Lilly and Company
criticalLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress | Eli Lilly and Company Skip to main content Email Alerts News Lilly.com OUTLINES --> Menu Menu Close Close Stock Info Expand mega menu Expand submenu Left icon for back button Back Stock Info Stock Quote & Chart Historic Price Lookup Investment Calculator Dividends & Stock Splits Webcasts & Presentations Financials Expand mega menu Expand submenu Left icon for back button Back Financials SEC Filings Annual Reports Quarterly Results Key Ratios Interactive Financ…
5 Aug 2026
Detected from official source — editorial confirmation pending
Eli Lilly and Company
criticalLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost
23 Jul 2026
Detected from official source — editorial confirmation pending
Weekly Briefing
The Retatrutide Report
One concise briefing covering the most important retatrutide clinical trial, research and regulatory developments.
No promotional content. Unsubscribe at any time.